Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 45 articles:
HTML format



Single Articles


    July 2021
  1. CORTES J, Rugo HS, Guo Z, Karantza V, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
    Lancet. 2021;398:24-25.
    PubMed    


  2. MASUDA J, Ozaki Y, Hara F, Kitano S, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer.
    Lancet. 2021;398:24.
    PubMed    


  3. MUSALLAM R, Alnajjar M, Al-Shurafa A, Bottcher B, et al
    Clinical and pathological characteristics and hormone receptor status of women with breast cancer in the European Gaza Hospital: a retrospective chart-based review.
    Lancet. 2021;398 Suppl 1:S38.
    PubMed     Abstract available


    April 2021
  4. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
    Breast cancer.
    Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
    PubMed     Abstract available


    December 2020
  5. CORTES J, Cescon DW, Rugo HS, Nowecki Z, et al
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020;396:1817-1828.
    PubMed     Abstract available


    November 2020
  6. MCCLELLAND S 3RD
    Breast cancer radiation therapy.
    Lancet. 2020;396:1559.
    PubMed    


  7. BRUNT AM, Haviland JS, Wheatley DA, Yarnold JR, et al
    Breast cancer radiation therapy - Authors' reply.
    Lancet. 2020;396:1559-1560.
    PubMed    


  8. OFFERSEN BV, Overgaard J
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558.
    PubMed    


  9. DOUEK M, De Silva-Minor S, Davies L, Jones B, et al
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558-1559.
    PubMed    


    September 2020
  10. DI COSIMO S
    Advancing immunotherapy for early-stage triple-negative breast cancer.
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31962.
    PubMed    


  11. MITTENDORF EA, Zhang H, Barrios CH, Saji S, et al
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31953.
    PubMed     Abstract available


    August 2020
  12. SESSLER DI
    Recurrence of breast cancer after anaesthesia - Author's reply.
    Lancet. 2020;396:377-378.
    PubMed    


  13. MORIS D, Kontos M
    Recurrence of breast cancer after anaesthesia.
    Lancet. 2020;396:376-377.
    PubMed    


  14. NIELSEN KC, Melton MS, Gebhard RE, Greengrass RA, et al
    Recurrence of breast cancer after anaesthesia.
    Lancet. 2020;396:376.
    PubMed    


  15. ISHIKAWA M, Sakamoto A, Ma D
    Recurrence of breast cancer after anaesthesia.
    Lancet. 2020;396:375-376.
    PubMed    


    July 2020
  16. GINSBURG O, Horton R
    A Lancet Commission on women and cancer.
    Lancet. 2020;396:11-13.
    PubMed    


    May 2020
  17. MURRAY BRUNT A, Haviland JS, Wheatley DA, Sydenham MA, et al
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Lancet. 2020;395:1613-1626.
    PubMed     Abstract available


    March 2020
  18. SPRING LM, Wander SA, Andre F, Moy B, et al
    Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Lancet. 2020;395:817-827.
    PubMed     Abstract available


    February 2020
  19. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.
    PubMed    


  20. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.
    PubMed    


  21. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.
    PubMed    


    January 2020
  22. CHUMSRI S, Thompson EA
    Carryover effects of aromatase inhibitors in prevention.
    Lancet. 2020;395:91-92.
    PubMed    


  23. THE LANCET
    Biosimilars: a new era in access to breast cancer treatment.
    Lancet. 2020;395:2.
    PubMed    


    December 2019
  24. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.
    PubMed    


  25. CUZICK J, Sestak I, Forbes JF, Dowsett M, et al
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Lancet. 2019 Dec 11. pii: S0140-6736(19)32955.
    PubMed     Abstract available


  26. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    PubMed     Abstract available


  27. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    PubMed     Abstract available


    October 2019
  28. SESSLER DI, Pei L, Huang Y, Fleischmann E, et al
    Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32313.
    PubMed     Abstract available


  29. ABDALLAH FW, Wijeysundera DN
    Anaesthetic interventions and long-term tumour recurrence.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32314.
    PubMed    


    August 2019
  30. KOTSOPOULOS J
    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.
    PubMed    



  31. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Abstract available


  32. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.
    PubMed    


    June 2019
  33. HURVITZ SA
    Is the duration of adjuvant trastuzumab debate still clinically relevant?
    Lancet. 2019;393:2565-2567.
    PubMed    


  34. PIVOT X, Romieu G, Debled M, Pierga JY, et al
    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30653.
    PubMed     Abstract available


  35. EARL HM, Hiller L, Vallier AL, Loi S, et al
    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30650.
    PubMed     Abstract available


    February 2019
  36. MUTEBI M
    Africa rising: gendered journeys of women patients and providers.
    Lancet. 2019;393:517-518.
    PubMed    


  37. HURVITZ SA
    Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
    Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.
    PubMed    



  38. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
    Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
    PubMed     Abstract available


    December 2018
  39. LEVY A, Chargari C, Deutsch E, Rivera S, et al
    Concerns about cardiotoxicity in the HERA trial.
    Lancet. 2018;390:2767.
    PubMed    


  40. CAMERON DA, Gelber RD, Procter M, Suter T, et al
    Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Lancet. 2018;390:2767-2768.
    PubMed    


    August 2018
  41. WILLER H
    Breast cancer in Venezuela: back to the 20th century.
    Lancet. 2018;392:461-462.
    PubMed    


    June 2018
  42. SHEIKH S, Sasieni P
    When should the errors in the UK's breast screening programme have been spotted?
    Lancet. 2018;391:2319-2320.
    PubMed    


    February 2018
  43. MCPHERSON K, Al Waheidi S
    The overestimation and the inappropriate promotion of the benefits of mammographic screening in breast cancer research and interventions in the Gaza Strip.
    Lancet. 2018;391 Suppl 2:S21.
    PubMed     Abstract available


    January 2018
  44. COLES CE, Haviland JS, Kirby AM, Titley J, et al
    Targeted radiotherapy for early breast cancer - Authors' reply.
    Lancet. 2018;391:27-28.
    PubMed    


  45. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Targeted radiotherapy for early breast cancer.
    Lancet. 2018;391:26-27.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: